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Department of Biochemistry. SUNY at Stony Brook. Stony Brook, New York 11794. 
The recent discovery of human ra___ss oncogenes by gene transfer experiments in cultured cells has 
added support to the genetic or mutational theory of cancer, ra___ss oncogenes are members of a 
multigene family which possess direct oncogenic potential in certain in vitro systems. The 
oncogenic potential of ra___~s genes is activated by somatic point mutations in their protein coding 
regions. These single base substitutions result in the synthesis of proteins containing single 
amino acid changes at these preferential positions, codon 12, 13 or 61. 
ras genes were originally identified as the transforming element of the Harvey and Kirsten 
strains of rat sarcoma viruses which arose through transduction of the rat H-ra___ss-1 and K-ras-2 
cellular genes, respectively. The ras genes also were identified by the NIH 3T3 transfection 
assay as the oncogenic principle in DNA preparations from human tumor cell lines. The three 
characterized human ra__~s genes are designated c-K-ra__~s, c-H-ras and N-ra__~s (i). 
The human c-K-ras oncogene was first identified as the transforming element of the SW480 (2) 
and SK-CO-I (3) colon carcinoma cell lines and of the Calu-i and SK-LU-I (3) lung carcinoma cell 
lines. The gene was originally described as the colon-lung carcinoma oncogene (4) due to its 
frequent association with these types of tumors (3,5) and was not characterized as a ra___ss oncogene 
until later (4,6) when it was found in other cell lines (5,7) and in primary human tumors (5). 
In our studies, we cloned and determined the structure of the c-K-ras gene from two lung 
adenocarclnomas, PR371 and PR310 (8). The mechanlms of activation were established as cysteine 
and histidine point mutations at codon 12 and 61, respectively. Similarly, mutant c-K-ras genes 
have been found and their mutations characterized in several other lung carcinoma cell lines 
(6,9) and primary tumors (10). However, the incidence of mutant c-K-ras genes in this common 
type of human cancer has not been accurately determined. Previous studies have used the NIH 3T3 
transfection assay to detect the c-K-ra___~s oncogene. However, this assay is not very sensitive and 
can lead to an underestimation of the real incidence of mutant ras genes, especially the c-K-ras 
gene due to its large size (8,6). Degradation of DNA from the tumor specimens, most likely 
caused by necrosis or by several cycles of freezing and thawing during surgery, collection and 
handling, may decrease the transforming efficiency to levels below detection. It is noteworthy 
that while a large number of tumor cell lines have been found to contain c-K-ras genes by the NIH 
3T3 focus assay (ii), only a few primary tumors scored positive by this method. This probably is 
due to the higher success rate in preparing undegraded DNA from cultured cells, and to the 
absence of contaminating normal cells in cell lines. 
Recently, other more sensitive methods have been developed, which are based on direct struc- 
tural identification of point mutations in DNA from tumor cells. A procedure capable of 
detecting all possible point mutations in ra___~s genes is based on differential hybridization of 
oligonucleotide probes of defined sequences to tumor DNAs. DNA isolated from a primary tumor is 
hybridized to various oligonucleotides with sequences specific for each one of the possible point 
mutations at different positions within the ra___~s genes. The mutant probes will not hybridize to 
the wild type DNA and hybridltatlon will only occur if the tumor contains a ras gene with the 
same mutation as the ollgonucleotide probe. The use of the polymerase chain reaction (PCR), has 
greatly increased the sensitivity of this method because amplification of the endogenous 
sequences on the order of 105 can be easily achieved. However, the method is somewhat cumbersome 
because a large number of probes are required to identify the presence of any of the possible 
mutations in each of the ras genes. Moreover, fluctuations in the extent of amplification 
obtained by the PCR technique, together with the presence of contaminating normal cells in the 
tumors, prevent an accurate estimation of the relative content of mutant ras alleles in the tumor 
cells. 
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During our studies on the c-K-ras human oncogene, we have developed a new method to detect and 
characterize single base substitutions in ras genes which also can be applied to other tran- 
scribed genes (12). The method, which we call the RNAse A mismatch cleavage method, is based on  
the ability of RNAse A to recognize and cleave single-base mismatches in RNA:RNA duplexes. Using 
this method we have analyzed the presence of mutant c-K-ras oncogenes in primary human tumors. 
Our previous findings have revealed a relatively high incidence (about 40%) of mutant c-K-ras 
oncogenes in colon carcinomas. In addition, we were able to detect mutant ras oncogenes in 
tumors at very early stages of development, including benign villous adenomas (13,14). 
We also have screened primary human lung tumors using the RNAse A mismatch cleavage method. An 
example of these experiments is given in Figure I. While the majority of tumors were negative 
for the mutant c-K-ras gene, as seen by a single protected band of 114 nucleotides present after 
digestion with RNAse A, one of these tumors yielded the two subbands diagnostic of a mismatch at 
the second position of codon 12 of the c-K-ras gene. 
Our results indicate that c-K-ras oncogenes with mutations at codon 12 are present in about 12% 
of primary human lung tumors (4 out of 35 total analyzed). However, the incidence is 
significatly higher (about 25%) if only adenocarcinomas of the lung are considered (4 out of 15). 
---I ! 
Zvrr  
310_  
234 
194 
118-e  
LUNG CARCINOMAS 
" " q lP  '~"," ap , ,  - -  M~.  ~ - -  - , , , ,  G ID  " "  
o .  Y o ( 
Figure I.- RNAse A mismatch cleavage analysis of primary human funs carcinomas. 
Total cellular RNA (30 ug each) prepared from Ii tumors and from human normal 
fibroblasts (HNF) and from tumor cell lines SK-CO-I and PR371 were hybridized to an antisense RNA 
probe corresponding to the serine mutation of the first coding exon of the human c-K-ras gene. 
After hybridization, the samples were digested with RNAse A and analyzed in a 8% denaturing 
polyacrylamide gel. The numbers at the left indicate the position and size (in nucleotides) of 
the Haelll digested 0X174 DNA used as molecular weight markers (M). The arrows to the right 
indicate the position of the subbands diagnostic of a mismatch at codon 12. 
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In any case, the incidence of c-K-ras oncogenes in human lung cancer is clearly lower than in 
colon cancer. Whether this difference is due to exposure to different carcinogens/mutagens or 
reflects some other factors related to the stage of cell growth or differentiation is not clear 
at present. It also appears that somatic mutational activation of the c-K-ras gene is not 
associated with a particular stage of tumor development because the degree of invasiveness of the 
positive tumors was diverse. One of these tumors was large in size but did not show signs of 
infiltration. A second tumor was very invaslve, but no metastases were detected in the lymph 
nodes at time of surgery and a third was very invasive with multiple metastases at surgery. 
Several lung squamous cell carcinomas have been reported to contain mutant c-K-ras genes, both 
in primary tumors (i0) and in cell lines (3). Therefore, the negative results obtained by our 
method with squamous cell carcinomas probably is due to the relativly small sample size. This is 
supported by previous characterizations of arginine and cysteine mutations (both which are caused 
by alterations at the first base of the triplet) in the positive cases reported. It is possible 
that our method could have missed these mutations. Although we have screened all these tumors 
with the anti normal probe, it is possible that if only a small proportion of tumor tissue (less 
than 25%) contained the mutant gent, the signal could have been below the background for 
detection. The use of an antisense RNA probe corresponding to the aspartic mutation could 
resolve this issue because in this case, as with the use of the serine probe, the sensitivity of 
the method will be sufficient to detect as little as 5-10% of mutant transcripts in the tumor RNA 
population. In any case, further studies with larger numbers of tumors will be required to 
obtain an accurate estimation of the incidence of c-K-ra____ss or other ras genes in lung tumors, the 
most frequent and lethal type of human cancer. 
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